$TCRT
Alaunos Therapeutics, Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514389572 Filed on October 30, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $340.0K $630.0K $200.0K
YoY Change 70.0% 215.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.850M $2.840M $3.070M
YoY Change -32.14% -7.49% -46.23%
% of Gross Profit
Research & Development $8.090M $9.733M $6.247M
YoY Change 197.43% 55.8% -61.47%
% of Gross Profit
Depreciation & Amortization $120.0K $120.0K $180.0K
YoY Change -25.0% -33.33% -10.0%
% of Gross Profit
Operating Expenses $10.94M $9.733M $6.247M
YoY Change 58.09% 55.8% -61.47%
Operating Profit -$10.60M -$11.94M -$9.115M
YoY Change 57.7% 31.01% -58.05%
Interest Expense $190.0K $5.850M -$7.410M
YoY Change -110.61% -178.95% -287.59%
% of Operating Profit
Other Income/Expense, Net $0.00 $2.000K -$191.0K
YoY Change -100.0% -101.05% 354.76%
Pretax Income -$10.40M -$6.090M -$16.71M
YoY Change 16.85% -63.55% -6.23%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.40M -$6.093M -$16.71M
YoY Change 16.83% -63.54% -6.23%
Net Earnings / Revenue -3059.12% -967.14% -8356.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.10 -$0.06 -$0.20
COMMON SHARES
Basic Shares Outstanding 102.7M shares 100.7M shares 83.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.80M $46.10M $23.60M
YoY Change -37.24% 95.34% -75.24%
Cash & Equivalents $42.80M $46.12M $23.63M
Short-Term Investments
Other Short-Term Assets $1.100M $1.500M $3.200M
YoY Change -42.11% -53.13% -55.56%
Inventory
Prepaid Expenses
Receivables $100.0K $200.0K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $44.09M $47.81M $27.28M
YoY Change -37.28% 75.3% -73.42%
LONG-TERM ASSETS
Property, Plant & Equipment $531.0K $654.0K $1.336M
YoY Change -33.71% -51.05% -36.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $491.0K $513.0K $739.0K
YoY Change -7.01% -30.58% -26.1%
Total Long-Term Assets $1.150M $1.295M $2.203M
YoY Change -21.07% -41.22% -26.57%
TOTAL ASSETS
Total Short-Term Assets $44.09M $47.81M $27.28M
Total Long-Term Assets $1.150M $1.295M $2.203M
Total Assets $45.24M $49.11M $29.48M
YoY Change -36.96% 66.6% -72.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.004M $1.953M $891.0K
YoY Change 374.88% 119.19% -78.79%
Accrued Expenses $7.182M $7.803M $11.57M
YoY Change 12.98% -32.58% -30.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.83M $11.70M $13.36M
YoY Change 38.96% -12.44% -38.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $20.00K $20.00K
YoY Change 2900.0% 0.0% -99.92%
Total Long-Term Liabilities $600.0K $20.00K $20.00K
YoY Change 2900.0% 0.0% -99.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.83M $11.70M $13.36M
Total Long-Term Liabilities $600.0K $20.00K $20.00K
Total Liabilities $11.40M $12.63M $25.85M
YoY Change -49.06% -51.13% -44.53%
SHAREHOLDERS EQUITY
Retained Earnings -$372.6M -$362.2M
YoY Change 9.32%
Common Stock $406.5M $398.7M $331.9M
YoY Change 5.13% 20.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.84M $36.48M $3.631M
YoY Change
Total Liabilities & Shareholders Equity $45.24M $49.11M $29.48M
YoY Change -36.96% 66.6% -72.09%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$10.40M -$6.093M -$16.71M
YoY Change 16.83% -63.54% -6.23%
Depreciation, Depletion And Amortization $120.0K $120.0K $180.0K
YoY Change -25.0% -33.33% -10.0%
Cash From Operating Activities -$9.870M -$10.49M -$15.50M
YoY Change 9.06% -32.32% 5.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $90.00K $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 -$90.00K $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.550M 3.700M 200.0K
YoY Change -87.79% 1750.0% 900.0%
NET CHANGE
Cash From Operating Activities -9.870M -10.49M -15.50M
Cash From Investing Activities 0.000 -90.00K 0.000
Cash From Financing Activities 6.550M 3.700M 200.0K
Net Change In Cash -3.320M -6.880M -15.30M
YoY Change -107.45% -55.03% 1.66%
FREE CASH FLOW
Cash From Operating Activities -$9.870M -$10.49M -$15.50M
Capital Expenditures $0.00 $90.00K $0.00
Free Cash Flow -$9.870M -$10.58M -$15.50M
YoY Change 8.94% -31.74% 2.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
102711484 shares
CY2013Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
65 Position
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23631000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102683984 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102683984 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.12
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5731490 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.94
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3257661 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.12
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49109000
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1700000
CY2014Q3 us-gaap Liabilities
Liabilities
12632000
CY2014Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
909000
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8235076 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5555864 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5792428 shares
CY2014Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
244000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11700000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
103000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1953000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-362211000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
398585000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7803000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
36477000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2014Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
665000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46122000
CY2014Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4800000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
654000
CY2014Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
208000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1457000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1484000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1441000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
498000
CY2014Q3 us-gaap Assets
Assets
49109000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
513000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
47814000
CY2014Q3 ziop Warrants Liability
WarrantsLiability
247000
CY2009Q4 ziop Estimated Fair Value Of Warrant
EstimatedFairValueOfWarrant
22900000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73306000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100159618 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100159618 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.01
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3471935 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10539767 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6747302 shares
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1933000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
212000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
3603000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7791000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
100000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
422000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340831000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
386511000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6357000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
49383000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71754000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2013Q4 us-gaap Liabilities
Liabilities
22371000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
1100000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
851000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68204000
CY2013Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
801000
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1948000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2654000
CY2013Q4 us-gaap Assets
Assets
71754000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
528000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
70297000
CY2013Q4 ziop Warrants Liability
WarrantsLiability
11776000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1551400 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.94
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-50464000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83051151 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16553734 shares
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
2979000
us-gaap Contracts Revenue
ContractsRevenue
600000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50992000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
250000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-190000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-262000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
391000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3717000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-194000
us-gaap Net Income Loss
NetIncomeLoss
-48203000
us-gaap Interest Paid
InterestPaid
0
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-5000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-600000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40133000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
8000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
20000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-49675000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
889000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
582000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
907000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
142000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4943000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-118000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
51592000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
956000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11459000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-618000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
201000
us-gaap Share Based Compensation
ShareBasedCompensation
2482000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
114300 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y4M28D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.26
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Trading Symbol
TradingSymbol
ZIOP
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>3. Recently Issued Accounting Pronouncements</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> On June&#xA0;10, 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915), which simplifies financial reporting for development stage entities by eliminating requirements specific to development stage entities. As a result, entities in a development stage will no longer need to present inception-to-date information about income statement line items, cash flows, and equity transactions. Instead, the new guidance clarifies how these entities should tailor existing disclosures to explain the risks and uncertainties related to their activities. This update is effective for annual periods beginning after December&#xA0;15, 2014, and early application is permitted for any annual or interim period for which the entity&#x2019;s financial statements have not yet been issued. The Company adopted this guidance in the quarter ended June&#xA0;30, 2014. The adoption of ASU 2014-10 impacted presentation and disclosure only and did not have any impact on financial position or results of operations.</p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.15
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26780000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
483536 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100360825 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M28D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.28
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M28D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.11
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14310937 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
585638 shares
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
11529000
us-gaap Contracts Revenue
ContractsRevenue
1033000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
63000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-464000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1323000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32903000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
132000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193000
us-gaap Net Income Loss
NetIncomeLoss
-21380000
us-gaap Interest Paid
InterestPaid
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3583000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1033000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24621000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-154000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
132000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22082000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
445000
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
339000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4891000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
692000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1447000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-193000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
33936000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1323000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9315000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1531000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3700000
us-gaap Share Based Compensation
ShareBasedCompensation
3583000
ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
3700000
CY2009 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11D
CY2013 ziop Revenue Recognition Period
RevenueRecognitionPeriod
P75M
CY2013Q2 us-gaap Severance Costs1
SeveranceCosts1
1700000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9496 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
125000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.47
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83161927 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0161 pure
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9564 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0174 pure
CY2013Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-7407000
CY2013Q3 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9115000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-191000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-16713000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6247000
CY2013Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9315000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3068000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
809000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.29
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0203 pure
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100428520 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9236 pure
CY2014Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5847000
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
633000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11942000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6093000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9733000
CY2014Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12575000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2842000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1148000

Files In Submission

Name View Source Status
0001193125-14-389572-index-headers.html Edgar Link pending
0001193125-14-389572-index.html Edgar Link pending
0001193125-14-389572.txt Edgar Link pending
0001193125-14-389572-xbrl.zip Edgar Link pending
d806040d10q.htm Edgar Link pending
d806040dex311.htm Edgar Link pending
d806040dex312.htm Edgar Link pending
d806040dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g806040tx_pg025new.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20140930.xml Edgar Link completed
ziop-20140930.xsd Edgar Link pending
ziop-20140930_cal.xml Edgar Link unprocessable
ziop-20140930_def.xml Edgar Link unprocessable
ziop-20140930_lab.xml Edgar Link unprocessable
ziop-20140930_pre.xml Edgar Link unprocessable